New Therapeutic Advances in Chronic Lymphocytic LeukemiaGhayathri Jeyakumar1* and Alessandra Ferrajoli2
- *Corresponding Author:
- Dr. Alessandra Ferrajoli
The University of Texas MD Anderson Cancer Center1515 Holcombe Blvd. Houston
TX 77030-4009, USA
Received date: May 14, 2014; Accepted date: July 22, 2014;; Published date: July 25, 2014
Citation: Jeyakumar G, Ferrajoli A (2014) New Therapeutic Advances in Chronic Lymphocytic Leukemia. J Leuk (Los Angel) 2:144. doi: 10.4172/2329-6917.1000144
Copyright: ©2014 Jeyakumar G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Treatment of Chronic Lymphocytic Leukemia (CLL) is entering a new era. In the last 5 years, several new exciting drugs have entered the realm in hopes for a success in curing the disease. The drugs fall into different classes such as BTK inhibitors, BCL-2 inhibitors, CD 20 Antibody, PI3 Kinase inhibitors, and Syk inhibitors. Numerous studies have shown that these agents have clinical activity both as initial therapy and as treatment of recurrent disease. Novel strategies combining or sequencing new agents with established chemotherapy and chemoimmunotherapies combinations are likely to change the treatment of CLL in the near future.